

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THE STUDY .....	1
INTENDED AUDIENCE.....	2
SCOPE OF REPORT .....	2
METHODOLOGY .....	3
INFORMATION SOURCES.....	3
ANALYST CREDENTIALS.....	3
RELATED BCC REPORTS .....	4
BCC ONLINE SERVICES.....	4
DISCLAIMER .....	4
 CHAPTER TWO: SUMMARY.....	 5
<i>SUMMARY TABLE GLOBAL VALUE OF BIOCHIP PRODUCTS BY     TYPE, THROUGH 2014 (\$ MILLIONS)</i> .....	 5
<i>SUMMARY FIGURE GLOBAL VALUE OF BIOCHIP PRODUCTS BY     TYPE, 2007-2014 (\$ MILLIONS)</i> .....	 6
SUMMARY (CONTINUED) .....	7
 CHAPTER THREE: OVERVIEW .....	 8
INTRODUCTION .....	8
INTRODUCTION (CONTINUED).....	9
<i>TABLE 1 BIOLOGY DOWNSIZING REVOLUTION</i> .....	10
<i>FIGURE 1 EVOLUTION OF BIOCHIPS</i> .....	10
INTRODUCTION (CONTINUED) .....	11
BIOCHIP TYPES .....	12
<i>FIGURE 2 CLASSIFICATION OF BIOCHIPS</i> .....	12
<i>TABLE 2 COMPARISON OF THE TWO MAJOR BIOCHIP TYPES</i> .....	13
BIOCHIP TYPES (CONTINUED).....	14
<i>TABLE 3 BIOCHIP NOMENCLATURE</i> .....	15
BIOCHIP TECHNOLOGIES COVERED IN THIS REPORT.....	16
<i>TABLE 4 SCOPE OF THIS REPORT</i> .....	16
WHAT IS NEW IN THIS REPORT.....	16
MARKET POTENTIAL OF BIOCHIPS.....	17
<i>TABLE 5 GLOBAL VALUE OF BIOCHIP PRODUCTS BY TYPE,         THROUGH 2014 (\$ MILLIONS)</i> .....	18
<i>TABLE 6 GLOBAL VALUE OF BIOCHIP MARKET BY END USE,         THROUGH 2014 (\$ MILLIONS)</i> .....	18
DRIVING FORCES FOR GROWTH IN BIOCHIPS MARKETS.....	19
<i>TABLE 7 PRIMARY FORCES DRIVING OVERALL BIOCHIPS         GROWTH</i> .....	20
DRIVING FORCES FOR ... (CONTINUED).....	21
BIOCHIPS: A CONVERGENCE OF DIVERSE TECHNOLOGIES.....	22
<i>TABLE 8 MULTIDISCIPLINARY FIELD OF BIOCHIPS</i> .....	22
LIFE CYCLE STATUS OF BIOCHIP PRODUCTS .....	23

<i>TABLE 9 LIFE CYCLE STATUS OF BIOCHIP TYPES</i> .....	23
COMMERCIAL STATUS OF BIOCHIPS .....	24
MICROARRAYS .....	24
LOAC .....	25
THE BIOCHIP INDUSTRY .....	25
<i>TABLE 10 BIOCHIP INDUSTRY KEY COMPETITORS</i> .....	25
THE BIOCHIP INDUSTRY (CONTINUED) .....	26
CHAPTER FOUR: MICROARRAY TECHNOLOGIES .....	27
INTRODUCTION .....	27
THE NANOSCALE WORLD .....	27
<i>TABLE 11 THE NANOSCALE WORLD</i> .....	27
<i>TABLE 12 MICROARRAY TYPES</i> .....	28
<i>TABLE 13 COMPARISON OF DNA AND PROTEIN MICROARRAY</i> <i>TECHNOLOGIES</i> .....	28
The Nanoscale World (Continued).....	29
DNA MICROARRAY TECHNOLOGIES .....	30
INTRODUCTION .....	30
<i>FIGURE 3 MICROARRAY FEATURE DENSITY</i> .....	30
<i>FIGURE 4 MICROARRAY RESOLUTION</i> .....	31
<i>TABLE 14 MICROARRAY GENOME CONTENT</i> .....	31
<i>TABLE 15 DNA MICROARRAY PLATFORM FEATURES</i> .....	32
<i>TABLE 16 DNA MICROARRAY PLATFORM COMPARISON FOR</i> <i>MAJOR MANUFACTURERS</i> .....	33
<i>TABLE 16 (CONTINUED)</i> .....	34
Introduction (Continued).....	35
STEPS IN THE DNA MICROARRAY EXPERIMENT .....	36
DNA MICROARRAY APPLICATIONS.....	36
<i>TABLE 17 DNA MICROARRAY APPLICATIONS</i> .....	37
Gene Expression Profiling.....	38
<i>TABLE 18 PROBES FOR GENE EXPRESSION DNA MICROARRAYS</i> .....	38
Gene Expression Profiling (Continued) .....	39
<i>TABLE 19 EXAMPLE APPLICATIONS OF GENE EXPRESSION</i> <i>PROFILING</i> .....	40
<i>FIGURE 5 GENETIC ANALYSIS TECHNOLOGY COMPETITIVE</i> <i>SPACE</i> .....	41
<i>TABLE 20 GENETIC ANALYSIS TECHNOLOGIES COMPARISON</i> .....	42
<i>FIGURE 6 RELATIVE NUMBER OF DISEASE-CAUSING ALLELES</i> <i>AT MAF5 AND MAF1</i> .....	43
<i>FIGURE 7 COMPETITIVE SPACE FOR GENE EXPRESSION</i> <i>ANALYSIS</i> .....	44
<i>FIGURE 8 APPLICATIONS SPACE WITH INTENSE TECHNOLOGY</i> <i>COMPETITION</i> .....	45
Gene Expression Profiling (Continued) .....	46

<i>TABLE 21 PLATFORMS FOR HIGH-THROUGHPUT QUANTITATIVE GENE EXPRESSION ANALYSIS</i> .....	47
<i>TABLE 22 GENE EXPRESSION PLATFORMS OF TWO LEADING DNA ARRAY MANUFACTURERS</i> .....	47
<i>TABLE 22 (CONTINUED)</i> .....	48
<i>TABLE 23 PROBE SENSITIVITY AND SPECIFICITY</i> .....	48
Gene Expression Profiling (Continued) .....	49
SNP Analysis .....	50
<i>FIGURE 9 SNP ANALYSIS PLATFORMS</i> .....	51
Epigenetic Analysis .....	52
<i>FIGURE 10 EPIGENOMICS WITHIN THE MOLECULAR BIOLOGY PARADIGM</i> .....	53
DNA Methylation .....	53
<i>FIGURE 11 EPIGENETIC CHANGES TO DNA AFFECT GENE EXPRESSION</i> .....	54
Histones .....	54
<i>FIGURE 12 HISTONE TAIL REGIONS MODIFIED BY HAT AND HDAC</i> .....	55
DNA Methylation and Histone Analysis Workflow .....	56
<i>FIGURE 13 UPSTREAM AND DOWNSTREAM STEPS IN EPIGENETIC ANALYSIS</i> .....	57
DNA Methylation Microarrays .....	57
ChIP-on-Chip .....	58
<i>TABLE 24 CHIP ASSAYS</i> .....	59
<i>TABLE 25 TECHNOLOGIES FOR MAPPING GENOMIC LOCATION OF CHROMATIN PROTEINS AND ENZYMES</i> .....	60
<i>TABLE 26 PLATFORMS FOR HIGH DENSITY OLIGONUCLEOTIDE EPIGENETICS ARRAYS</i> .....	61
Cytogenetic Analysis .....	61
<i>TABLE 27 COMPARISON OF CHROMOSOMAL CHANGE DETECTION TECHNOLOGIES</i> .....	62
<i>FIGURE 14 COMPETITIVE SPACE FOR CNV ANALYSIS</i> .....	63
Cytogenetic Analysis (Continued).....	64
<i>TABLE 28 CGH MICROARRAY PROBE PLATFORMS</i> .....	65
<i>TABLE 29 CGH MICROARRAY TRENDS</i> .....	66
Cytogenetic Analysis (Continued).....	67
<i>TABLE 30 FUTURE TECHNOLOGY NEEDS FOR CGH MICROARRAYS</i> .....	68
miRNA Analysis .....	69
<i>TABLE 31 WORKFLOW FOR AN MIRNA EXPERIMENT</i> .....	70
<i>TABLE 32 TECHNICAL CHALLENGES FOR MIRNAS</i> .....	71
ARRAYS ON BEADS .....	72
<i>TABLE 33 ARRAYS ON BEADS VERSUS PLANAR MICROARRAYS</i> .....	72
CATALOG AND CUSTOM DNA MICROARRAYS .....	72

SUPPLY OF REAGENTS AND SAMPLE PREPARATION FOR MICROARRAYS .....	73
TOXICOGENOMICS .....	74
DNA SEQUENCING.....	75
<i>FIGURE 15 COMPARISON OF SANGER WITH UHTS DNA SEQUENCING TECHNOLOGIES.....</i>	<i>76</i>
<i>TABLE 34 SMS TECHNOLOGY.....</i>	<i>77</i>
<i>TABLE 35 COMPARISON OF SELECTED DNA SEQUENCING PLATFORMS.....</i>	<i>78</i>
<i>FIGURE 16 COMPETITIVE SPACE FOR HIGH-THROUGHPUT GENOMIC ANALYSIS.....</i>	<i>79</i>
<i>TABLE 36 BIOCHIP CONTENT IN NHGRI GRANTEES FOR NEXT- GENERATION DNA SEQUENCING, 2005.....</i>	<i>80</i>
<i>TABLE 36 (CONTINUED).....</i>	<i>81</i>
<i>TABLE 37 NEXT-GENERATION DNA SEQUENCING COMPANIES.....</i>	<i>82</i>
RESEQUENCING APPROACHES IN DIAGNOSTICS.....	82
DNA MICROARRAY MANUFACTURING .....	83
<i>FIGURE 17 DNA MICROARRAY MANUFACTURING TECHNOLOGIES .....</i>	<i>83</i>
DNA Microarray Manufacturing (Continued).....	84
<i>TABLE 38 DNA MICROARRAY PROBE DENSITY TRENDS, FEATURES PER CHIP, 1996–2009.....</i>	<i>85</i>
DNA MICROARRAY TECHNOLOGY TRENDS.....	85
DNA MICROARRAY TECHNOLOGY CHALLENGES .....	86
<i>FIGURE 18 DNA MICROARRAY COST-VOLUME CURVE .....</i>	<i>87</i>
PROTEIN MICROARRAY TECHNOLOGIES .....	88
INTRODUCTION.....	88
<i>FIGURE 19 IMPORTANCE OF PROTEINS.....</i>	<i>88</i>
PROTEOMICS WORKFLOW .....	89
<i>FIGURE 20 PROTEIN ANALYSIS APPROACHES CONTRASTED .....</i>	<i>89</i>
PROTEIN MICROARRAY DESIGN FEATURES .....	90
<i>TABLE 39 PROTEIN MICROARRAY PLATFORMS .....</i>	<i>90</i>
PROTEIN MICROARRAY APPLICATIONS AS RESEARCH TOOLS.....	91
<i>TABLE 40 PROTEIN MICROARRAYS AS RESEARCH TOOLS.....</i>	<i>92</i>
PROTEIN MICROARRAY TYPES .....	93
<i>TABLE 41 PROTEIN MICROARRAY PRODUCT TYPES.....</i>	<i>93</i>
Protein Microarray Types (Continued).....	94
PROTEIN MICROARRAY TECHNOLOGY CHALLENGES .....	95
<i>TABLE 42 PROTEIN MICROARRAY TECHNICAL CHALLENGES .....</i>	<i>96</i>
Protein Microarray Technology Challenges (Continued).....	97
PROTEIN MICROARRAY TECHNOLOGY TRENDS.....	98
<i>TABLE 43 PROTEIN MICROARRAY TECHNOLOGY TRENDS .....</i>	<i>98</i>
EMERGING MICROARRAY TECHNOLOGIES .....	99
<i>TABLE 44 EMERGING MICROARRAY TECHNOLOGIES .....</i>	<i>99</i>

GLYCOMICS MICROARRAYS .....	100
Glycomics Microarrays (Continued) .....	101
TMAS .....	102
FCMS .....	103
<i>TABLE 45 U.S. GOVERNMENT INITIATIVES PROMOTING</i>	
<i>EMERGING MICROARRAYS</i> .....	104
MICROARRAY TECHNOLOGY TRENDS.....	105
<i>TABLE 46 MICROARRAY TECHNOLOGY TRENDS</i> .....	105
MICROARRAY TECHNOLOGY TRENDS (CONTINUED) .....	106
 CHAPTER FIVE: LOAC TECHNOLOGIES .....	107
INTRODUCTION .....	107
<i>TABLE 47 MICROFLUIDICS PRODUCT LIFE CYCLE STAGE</i> .....	107
<i>TABLE 48 LOAC SUBSTRATE TECHNOLOGIES</i> .....	108
LOAC TYPES .....	109
<i>TABLE 49 LOAC TYPES</i> .....	109
IN VITRO PROTEOMICS .....	109
ELECTROPHORESIS ON A CHIP .....	110
STRUCTURAL PROTEOMICS .....	110
PCR ON A CHIP .....	111
IMMUNOASSAYS ON A CHIP .....	112
Immunoassays on a Chip (Continued).....	113
<i>TABLE 50 IMMUNOASSAY-ON-A-CHIP APPLICATIONS</i> .....	114
LOAC APPLICATIONS .....	114
<i>TABLE 51 LOAC MARKET SEGMENTS</i> .....	115
<i>TABLE 52 MICROFLUIDIC SYSTEMS ADVANTAGES FOR</i>	
<i>BIOCHEMICAL ANALYSIS</i> .....	116
LOAC KEY TECHNOLOGY TRENDS .....	116
<i>TABLE 53 LOAC KEY TECHNOLOGY TRENDS</i> .....	117
<i>TABLE 54 LOAC TECHNOLOGY PLATFORMS</i> .....	118
LOAC TECHNOLOGY CHALLENGES .....	119
<i>TABLE 55 LOAC TECHNOLOGY CHALLENGES</i> .....	120
 CHAPTER SIX: BIOCHIP APPLICATIONS IN DRUG DISCOVERY AND	
DEVELOPMENT .....	121
BIOCHIP MARKET SEGMENTATION .....	121
<i>TABLE 56 BIOCHIP KEY LIFE SCIENCES MARKET SEGMENTS</i> .....	121
DRUG DISCOVERY AND DEVELOPMENT.....	122
<i>TABLE 57 DRUG R&amp;D INVESTMENT BY STAGE, 2003 (%)</i> .....	123
DRUG INDUSTRY CHALLENGES.....	123
OVERVIEW OF THE DRUG DISCOVERY AND	
DEVELOPMENT PROCESS.....	124
<i>FIGURE 21 DRUG DISCOVERY AND DEVELOPMENT TIMESCALE</i> .....	124
<i>TABLE 58 BIOCHIP APPLICATIONS IN DRUG DISCOVERY AND</i>	
DEVELOPMENT.....	125

<i>TABLE 58 (CONTINUED)</i> .....	126
DRUG TARGET IDENTIFICATION .....	127
DRUG DISCOVERY.....	127
Structural Biology .....	127
Lead Generation .....	128
Lead Generation (Continued).....	129
Lead Generation (Continued).....	130
Lead Optimization.....	131
Process R&D .....	132
Preclinical and Clinical Trials .....	132
NEEDS IN THE DRUG DISCOVERY AND DEVELOPMENT	
PROCESS.....	132
<i>TABLE 59 KEY NEEDS IN DRUG DISCOVERY AND DEVELOPMENT</i> .....	132
<i>TABLE 59 (CONTINUED)</i> .....	133
Needs in the Drug Discovery and ... (Continued).....	133
Needs in the Drug Discovery and ... (Continued).....	134
<i>FIGURE 22 VALIDATION GAP FOR FUTURE DRUG TARGETS</i>	
<i>(NUMBER OF POTENTIAL DRUG TARGETS)</i> .....	135
Needs in the Drug Discovery and ... (Continued).....	136
CHAPTER SEVEN: BIOCHIP APPLICATIONS IN DIAGNOSTICS .....	137
INTRODUCTION .....	137
DRIVING FORCES FOR ADOPTION OF BIOCHIP DIAGNOSTIC	
PLATFORMS.....	137
BIOMARKER DISCOVERY AND VALIDATION .....	137
CLINICAL ACCEPTANCE OF BIOMARKER-BASED TESTS .....	138
<i>TABLE 60 RATE OF ADOPTION OF DNA MICROARRAY</i>	
<i>DIAGNOSTICS TESTS</i> .....	139
MICROARRAY STANDARDIZATION EFFORTS .....	140
Microarray Quality Control Project.....	140
External RNA Controls Consortium (ERCC) Study .....	141
Association of Biomolecular Resource Facilities (ABRF)	
CGH Microarray Platform Study .....	142
<i>TABLE 61 COMPARISON OF ARRAY-CGH PLATFORMS</i> .....	142
OVERVIEW OF MDX.....	143
INTRODUCTION.....	143
BENEFITS OF BIOCHIPS AS AN MDX PLATFORM .....	144
Benefits of Biochips as an MDx Platform (Continued) .....	145
<i>FIGURE 23 BIOCHIPS TARGET HIGH GROWTH, HIGH MARGIN</i>	
<i>PORTION OF THE IVD MARKET</i> .....	146
<i>TABLE 62 BIOTECHNOLOGY DRUGS APPROVED BY THE FDA,</i>	
<i>1980–2008 (NUMBER)</i> .....	147
PHARMACOGENOMICS TESTS .....	147
Pharmacogenomics Tests (Continued).....	148
STRATEGIES FOR COMMERCIALIZING PGX TESTS.....	149

MDX MARKET PENETRATION CHALLENGES .....	150
<i>TABLE 63 COMPARISON OF DNA-BASED MDX PLATFORMS</i> .....	151
<i>TABLE 64 FACTORS AFFECTING PENETRATION OF BIOCHIPS</i> <i>INTO THE MDX MARKET</i> .....	152
MDX Market Penetration Challenges (Continued).....	153
MDX MARKET SEGMENTS.....	154
MDX TEST SENSITIVITY AND SPECIFICITY .....	155
<i>FIGURE 24 SENSITIVITY AND SPECIFICITY</i> .....	156
STATUS OF BIOCHIPS DIAGNOSTICS BY INDICATION .....	157
SUMMARY OF BIOCHIPS DIAGNOSTICS .....	157
CANCER OVERVIEW .....	157
<i>TABLE 65 U.S. INCIDENCE AND TREATMENT DECISIONS FOR</i> <i>SELECTED CANCERS, 2009</i> .....	157
HEMATOLOGICAL CANCERS .....	158
BLADDER CANCER.....	158
BREAST CANCER.....	159
Breast Cancer Screening.....	159
Prognosis and Pharmacogenetics Tests.....	160
<i>FIGURE 25 BREAST CANCER TREATMENT DECISION TREE FOR</i> <i>ONCOTYPE DX</i> .....	161
<i>TABLE 66 ESTIMATED NUMBER OF ANNUAL BREAST CANCER</i> <i>TREATMENT DECISIONS IN THE U.S. BY CANCER</i> <i>CLASSIFICATION</i> .....	162
Breast Cancer MDx Platforms .....	162
<i>TABLE 67 BREAST CANCER MDX TECHNOLOGY PLATFORMS</i> .....	163
Breast Cancer Multivariate Diagnostic Tests .....	164
<i>TABLE 68 COMMERCIAL LANDSCAPE FOR MULTIVARIATE</i> <i>BREAST CANCER TESTS, BY PARAMETER</i> .....	164
<i>TABLE 68 (CONTINUED)</i> .....	165
Breast Cancer Multivariate ... (Continued) .....	166
Regulatory Status of Gene Profiling Diagnostic Tests.....	167
<i>TABLE 69 FDA REGULATORY POSITION ON IVDMA</i> .....	167
CERVICAL CANCER.....	168
<i>TABLE 70 COMMERCIAL LANDSCAPE FOR HPV TESTS</i> .....	168
<i>TABLE 70 (CONTINUED)</i> .....	169
COLORECTAL CANCER .....	170
Conventional Colorectal Cancer Screening Tests .....	170
<i>TABLE 71 CURRENT SCREENING AND DIAGNOSTICS TESTS FOR</i> <i>COLORECTAL CANCER</i> .....	171
Molecular Colorectal Cancer Diagnostics Tests .....	172
<i>TABLE 72 COMMERCIAL LANDSCAPE FOR COLORECTAL</i> <i>MOLECULAR TESTS</i> .....	172
Molecular Colorectal Cancer ... (Continued) .....	173
CUP .....	174

<i>TABLE 73 COMMERCIAL MDX PLATFORMS FOR TISSUE OF ORIGIN TESTS</i> .....	175
GASTRIC CANCER .....	176
LUNG CANCER .....	177
Lung Cancer (Continued) .....	178
OVARIAN CANCER .....	179
<i>TABLE 74 OVARIAN CANCER SCREENING TESTS</i> .....	179
<i>TABLE 75 OVARIAN CANCER DIAGNOSTIC TEST STATUS</i> .....	180
PANCREATIC CANCER .....	180
PEDIATRIC CANCERS .....	181
PROSTATE CANCER .....	181
Prostate Cancer (Continued) .....	182
COMPREHENSIVE CANCER TESTS .....	183
STATUS OF BIOCHIP-BASED INFECTIOUS DISEASE DIAGNOSTICS .....	183
SEPSIS .....	183
TUBERCULOSIS .....	184
MRSA .....	184
INFLUENZA .....	185
OTHER INFECTIOUS DISEASES .....	185
STATUS OF BIOCHIP-BASED DME DIAGNOSTICS .....	186
DMES .....	186
<i>TABLE 76 MICROARRAY-BASED DME DIAGNOSTICS TESTS</i> .....	186
DMEs (Continued) .....	187
WARFARIN DOSING .....	188
<i>TABLE 77 WARFARIN CYP PGX DIAGNOSTICS TEST COMPETITOR SPACE</i> .....	189
<i>TABLE 77 (CONTINUED)</i> .....	190
Warfarin Dosing (Continued) .....	191
<i>TABLE 78 CYP450 GENE FAMILY PHARMACOGENETIC DIAGNOSTIC GLOBAL TEST MARKET POTENTIAL, 2009 (\$ MILLIONS)</i> .....	192
STATUS OF BIOCHIP-BASED NEUROLOGICAL DIAGNOSTICS .....	192
ALZHEIMERS DISEASE .....	192
SCHIZOPHRENIA .....	193
STATUS OF BIOCHIP-BASED HEART DISEASE DIAGNOSTICS .....	193
CHF FAILURE .....	193
<i>TABLE 79 BNP MDX TESTS FOR CHF</i> .....	194
CHF Failure (Continued) .....	195
OTHER CARDIAC DIAGNOSTICS .....	196
STATUS OF BIOCHIP-BASED DIAGNOSTICS FOR CF .....	197
<i>TABLE 80 CF BIOCHIP DIAGNOSTIC PLATFORMS</i> .....	197
STATUS OF BIOCHIP-BASED DIAGNOSTICS FOR PRE- AND POST-NATAL .....	198



STATUS OF BIOCHIP-BASED DIAGNOSTICS FOR IMMUNE DISEASES .....	199
HLA TYPING TESTS .....	199
AUTOIMMUNE TESTING.....	200
STATUS OF BIOCHIP-BASED DIAGNOSTICS FOR FOOD SAFETY/QC.....	201
TABLE 81 BIOCHIPS STATUS IN FOOD SAFETY/QC MARKET .....	201
STATUS OF BIOCHIP- ... (CONTINUED) .....	202
CHAPTER EIGHT: BIOCHIP MARKET GROWTH DRIVING FORCES.....	203
INTRODUCTION .....	203
FIGURE 26 GROWTH IN SCIENTIFIC PUBLICATIONS RELATED TO MICROARRAYS AND LAB ON A CHIP, 2000–2009 (NUMBER OF PUBMED CITATIONS).....	203
FIGURE 26 (CONTINUED) .....	204
BIOCHIP GROWTH DRIVING FORCES.....	204
TABLE 82 PRIMARY FORCES DRIVING OVERALL BIOCHIPS GROWTH.....	205
FUNDING FOR LIFE SCIENCE RESEARCH .....	205
TABLE 83 STIMULUS FUNDING ALLOCATED TO U.S. SCIENCE SPENDING, 2009 (\$ MILLIONS).....	206
FIGURE 27 NIH ANNUAL FUNDING BUDGET, 2000–2009 (\$ BILLIONS).....	206
LARGE-SCALE GENOMIC, PROTEOMIC, AND BIOCHIP INITIATIVES .....	207
TABLE 84 RESEARCH INITIATIVES DRIVING BIOCHIP GROWTH, 1999–2008.....	208
Large-scale Genomic, Proteomic, ... (continued).....	209
NEED FOR MORE EFFICIENT DRUG DISCOVERY AND DEVELOPMENT PROCESS.....	210
GROWTH IN PERSONALIZED MEDICINE .....	210
NEED FOR EARLY DETECTION OF CANCERS.....	211
AGING POPULATIONS .....	211
NEW DISCOVERIES IN GENOMICS AND PROTEOMICS .....	212
MINIATURIZATION OF BIOCHIPS.....	212
DECLINE IN GENETIC ANALYSIS COSTS.....	212
DISCOVERY OF GENE- AND SNP-DISEASE ASSOCIATIONS.....	213
CHAPTER NINE: BIOCHIP MARKETS .....	214
GLOBAL BIOCHIP MARKET .....	214
TABLE 85 GLOBAL VALUE OF BIOCHIP PRODUCTS BY TYPE, THROUGH 2014 (\$ MILLIONS).....	214
TABLE 86 GLOBAL VALUE OF BIOCHIP MARKET BY END USE, THROUGH 2014 (\$ MILLIONS).....	215
MICROARRAY MARKETS .....	216

<i>TABLE 87 GLOBAL VALUE OF MICROARRAYS BY TYPE, THROUGH 2014 (\$ MILLIONS)</i> .....	216
DNA MICROARRAY MARKETS .....	217
DNA MICROARRAY MARKET BY APPLICATION.....	217
<i>TABLE 88 GLOBAL VALUE OF DNA MICROARRAYS BY APPLICATION, THROUGH 2014 (\$ MILLIONS)</i> .....	217
DNA Microarray Market by Application (Continued) .....	218
<i>FIGURE 28 ENTRIES TO MIRNA DATABASE, 2002–2009 (NUMBER)</i> .....	219
<i>TABLE 89 GLOBAL VALUE OF GENOTYPING DNA MICROARRAYS BY APPLICATION, THROUGH 2014 (\$ MILLIONS)</i> .....	220
DNA MICROARRAY MARKET BY END-USE INDUSTRY .....	220
<i>TABLE 90 GLOBAL VALUE OF DNA MICROARRAYS BY END USE, THROUGH 2014 (\$ MILLIONS)</i> .....	221
DNA MICROARRAY MARKET BY FORMAT .....	222
<i>TABLE 91 GLOBAL VALUE OF DNA MICROARRAYS BY FORMAT, THROUGH 2014 (\$ MILLIONS)</i> .....	222
BIOCHIPS DIAGNOSTICS MARKETS .....	223
BIOCHIPS DIAGNOSTIC MARKET BY APPLICATION .....	223
<i>TABLE 92 GLOBAL VALUE OF DIAGNOSTIC BIOCHIPS BY APPLICATION, THROUGH 2014 (\$ MILLIONS)</i> .....	224
Biochips Diagnostic Market by Application (Continued).....	225
BIOCHIP DIAGNOSTICS MARKET BY BIOCHIP TYPE.....	226
<i>TABLE 93 GLOBAL VALUE OF DIAGNOSTIC BIOCHIPS BY TYPE, THROUGH 2014 (\$ MILLIONS)</i> .....	226
CANCER DIAGNOSTICS BIOCHIPS MARKET BY INDICATION .....	227
<i>TABLE 94 GLOBAL VALUE OF CANCER DIAGNOSTIC BIOCHIPS BY INDICATION, THROUGH 2014 (\$ MILLIONS)</i> .....	227
Cancer Diagnostics Biochips Market ... (Continued).....	228
CANCER DIAGNOSTICS BIOCHIPS MARKET BY BIOCHIP TYPE .....	229
<i>TABLE 95 GLOBAL VALUE OF CANCER DIAGNOSTIC BIOCHIPS BY TYPE, THROUGH 2014 (\$ MILLIONS)</i> .....	229
<i>TABLE 96 ADOPTION RATE FOR DNA MICROARRAYS IN DIAGNOSTICS</i> .....	230
DIAGNOSTIC DNA MICROARRAYS MARKET BY ANALYSIS METHOD .....	231
<i>TABLE 97 GLOBAL VALUE OF DIAGNOSTIC DNA MICROARRAYS BY ANALYSIS METHOD, THROUGH 2014 (\$ MILLIONS)</i> .....	231
Diagnostic DNA Microarrays Market ... (Continued).....	232
DIAGNOSTIC DNA MICROARRAYS MARKET BY DIAGNOSTIC FUNCTION .....	233
<i>TABLE 98 GLOBAL VALUE OF DNA MICROARRAYS DIAGNOSTICS BY DIAGNOSTIC FUNCTION, THROUGH 2014 (\$ MILLIONS)</i> .....	233

DIAGNOSTIC PROTEIN MICROARRAY MARKET BY TECHNOLOGY.....	234
<i>TABLE 99 GLOBAL VALUE OF PROTEIN MICROARRAY DIAGNOSTICS MARKET BY TECHNOLOGY, THROUGH 2014 (\$ MILLIONS)</i> .....	<i>235</i>
PROTEIN MICROARRAYS MARKETS.....	236
PROTEIN MICROARRAYS MARKETS BY TECHNOLOGY.....	236
<i>TABLE 100 GLOBAL VALUE OF PROTEIN MICROARRAYS BY TECHNOLOGY, THROUGH 2014 (\$ MILLIONS)</i> .....	<i>236</i>
Protein Microarrays Markets by Technology (Continued).....	237
PROTEIN MICROARRAYS MARKET BY PRODUCT FORMAT.....	238
<i>TABLE 101 GLOBAL VALUE OF PROTEIN MICROARRAYS BY PRODUCT FORMAT, THROUGH 2014 (\$ MILLIONS)</i> .....	<i>238</i>
<i>TABLE 102 COATED MICROARRAY SLIDE MARKET PRINCIPAL COMPETITORS</i> .....	<i>239</i>
PROTEIN MICROARRAYS MARKET BY END-USE INDUSTRY.....	240
<i>TABLE 103 GLOBAL VALUE OF PROTEIN MICROARRAYS BY END USE, THROUGH 2014 (\$ MILLIONS)</i> .....	<i>240</i>
EMERGING MICROARRAYS MARKETS.....	241
EMERGING MICROARRAYS MARKET BY TECHNOLOGY.....	241
<i>TABLE 104 GLOBAL VALUE OF EMERGING MICROARRAYS BY TECHNOLOGY, THROUGH 2014 (\$ MILLIONS)</i> .....	<i>241</i>
EMERGING MICROARRAYS MARKETS BY END-USE INDUSTRY.....	242
<i>TABLE 105 GLOBAL VALUE OF EMERGING MICROARRAYS BY END-USE INDUSTRY, THROUGH 2014 (\$ MILLIONS)</i> .....	<i>243</i>
LOAC MARKETS.....	243
VALUE OF LOAC DEVICES BY END-USE INDUSTRY.....	243
<i>TABLE 106 GLOBAL VALUE OF LOAC DEVICES BY END-USE INDUSTRY, THROUGH 2014 (\$ MILLIONS)</i> .....	<i>244</i>
Value of LOAC Devices by End-Use Industry (Continued).....	245
Value of LOAC Devices by End-Use Industry (Continued).....	246
Value of LOAC Devices by End-Use Industry (Continued).....	247
LOAC DRUG DISCOVERY AND DEVELOPMENT MARKET BY APPLICATION.....	248
<i>TABLE 107 GLOBAL VALUE OF LOAC DRUG DISCOVERY AND DEVELOPMENT MARKET BY APPLICATION, THROUGH 2014 (\$ MILLIONS)</i> .....	<i>249</i>
LOAC Drug Discovery and Development ... (Continued).....	250
LOAC DIAGNOSTICS MARKET BY APPLICATION.....	251
<i>TABLE 108 GLOBAL VALUE OF LOAC DEVICES DIAGNOSTICS MARKET BY APPLICATION, THROUGH 2014 (\$ MILLIONS)</i> .....	<i>252</i>
LOAC Diagnostics Market by Application (Continued).....	253

BIOCHIPS GEOGRAPHIC MARKETS .....	254
GLOBAL VALUE OF BIOCHIPS PRODUCTS BY GEOGRAPHY .....	254
<i>TABLE 109 GLOBAL VALUE OF BIOCHIP PRODUCTS BY GEOGRAPHY, THROUGH 2014 (\$ MILLIONS)</i> .....	255
MICROARRAY GEOGRAPHICAL MARKETS .....	255
<i>TABLE 110 GLOBAL VALUE OF DNA MICROARRAYS BY GEOGRAPHIC REGION, THROUGH 2014 (\$ MILLIONS)</i> .....	256
<i>TABLE 111 GLOBAL VALUE OF PROTEIN MICROARRAYS BY GEOGRAPHIC REGION, THROUGH 2014 (\$ MILLIONS)</i> .....	257
<i>TABLE 112 GLOBAL VALUE OF EMERGING MICROARRAYS BY GEOGRAPHIC REGION, THROUGH 2014 (\$ MILLIONS)</i> .....	257
LOAC GEOGRAPHICAL MARKETS .....	258
<i>TABLE 113 GLOBAL VALUE OF LOAC BY GEOGRAPHIC REGION, THROUGH 2014 (\$ MILLIONS)</i> .....	258
 CHAPTER TEN: INDUSTRY DYNAMICS.....	259
INTRODUCTION .....	259
RECENT ACQUISITIONS IN THE BIOCHIP INDUSTRY.....	259
<i>TABLE 114 KEY ACQUISITIONS IN BIOCHIP INDUSTRY, 2007–2009</i> .....	260
RECENT ACQUISITIONS IN THE BIOCHIP ... (CONTINUED)....	261
RECENT ACQUISITIONS IN THE BIOCHIP ... (CONTINUED)....	262
RECENT ACQUISITIONS IN THE BIOCHIP ... (CONTINUED)....	263
DNA MICROARRAYS COMPETITIVE LANDSCAPE.....	264
<i>TABLE 115 LEADING DNA MICROARRAY SUPPLIERS</i> .....	264
<i>TABLE 115 (CONTINUED)</i> .....	265
SOURCES OF COMPETITIVE ADVANTAGE IN DNA MICROARRAYS .....	265
SOURCES OF COMPETITIVE ... (CONTINUED).....	266
<i>TABLE 116 DNA MICROARRAY AND SEQUENCING COMPETITOR STRENGTHS AND WEAKNESSES</i> .....	267
NEXT GENERATION SEQUENCING COMPETITIVE LANDSCAPE .....	268
<i>TABLE 117 NUMBER OF SECOND-GENERATION GENOME SEQUENCING INSTRUMENTS AT MAJOR SEQUENCING CENTERS, 2009</i> .....	269
DIAGNOSTICS BIOCHIP STRATEGIC ALLIANCES.....	269
<i>TABLE 118 BIOCHIP STRATEGIC ALLIANCES IN DIAGNOSTICS</i> .....	270
DIAGNOSTICS BIOCHIP STRATEGIC ... (CONTINUED) .....	271
PROTEIN MICROARRAY SUPPLIERS.....	272
<i>TABLE 119 PROTEIN AND SPECIALTY MICROARRAY SUPPLIERS BY MICROARRAY TECHNOLOGY</i> .....	272
LOAC COMPETITIVE LANDSCAPE.....	273
<i>TABLE 120 LOAC COMPETITOR LANDSCAPE, BY COMPANY</i> .....	273
<i>TABLE 120 (CONTINUED)</i> .....	274
<i>TABLE 120 (CONTINUED)</i> .....	275

CHAPTER ELEVEN: PATENTS .....	276
INTRODUCTION .....	276
BIOCHIP INDUSTRY PATENT STATUS .....	276
<i>FIGURE 29 ANNUAL ISSUED DNA MICROARRAY PATENTS BY</i> <i>REGION, 2001–2009 (NUMBER)</i> .....	277
<i>FIGURE 30 ANNUAL ISSUED PROTEIN MICROARRAY PATENTS BY</i> <i>REGION, 2001–2009 (NUMBER OF PATENTS GRANTED)</i> .....	278
<i>FIGURE 31 ANNUAL ISSUED LOAC PATENTS BY GEOGRAPHY,</i> <i>2001–2009 (NUMBER)</i> .....	279
BIOCHIP COMPANY PATENT STATUS .....	280
<i>TABLE 121 ISSUED PATENTS AND PATENT APPLICATIONS FOR</i> <i>SELECTED MICROARRAY COMPANIES (NUMBER)</i> .....	280
<i>FIGURE 32 ISSUED PATENTS AND PATENT APPLICATIONS FOR</i> <i>SELECTED MICROARRAY COMPANIES, BY REGION (NUMBER)</i> .....	281
<i>FIGURE 32 (CONTINUED)</i> .....	282
<i>TABLE 122 ISSUED PATENTS AND PATENT APPLICATIONS FOR</i> <i>SELECTED LOAC COMPANIES (NUMBER)</i> .....	283
<i>FIGURE 33 ISSUED PATENTS AND PATENT APPLICATIONS FOR</i> <i>SELECTED LOAC COMPANIES (NUMBER)</i> .....	284
BIOCHIP PATENT LITIGATION STATUS.....	284
<i>TABLE 123 STATUS OF LIGITATION ISSUES IN THE BIOCHIP</i> <i>INDUSTRY</i> .....	285
INDIVIDUAL PATENT STATUS OF SELECTED BIOCHIP COMPANIES .....	285
AFFYMETRIX POSITION.....	285
COMBIMATRIX POSITION.....	286
ILLUMINA POSITION .....	287
CALIPER POSITION.....	287
ROCHE-NIMBLEGEN POSITION .....	288
CHAPTER TWELVE: COMPANY PROFILES .....	289
20/20 GENE SYSTEMS, INC. ....	289
ABBOTT LABORATORIES.....	290
ABTECH SCIENTIFIC, INC.....	290
ADVANCED LIQUID LOGIC, INC. ....	291
AFFYMETRIX, INC.....	292
AFFYMETRIX, INC. (CONTINUED) .....	293
<i>TABLE 124 AFFYMETRIX STRATEGIC ALLIANCES</i> .....	294
AFFYMETRIX, INC. (CONTINUED) .....	295
AGENDIA BV.....	296
<i>TABLE 125 AGENDIA MICROARRAY-BASED DIAGNOSTICS</i> <i>PIPELINE</i> .....	296
AGENDIA BV (CONTINUED) .....	297
AGILENT TECHNOLOGIES, INC. ....	298
AGILENT TECHNOLOGIES, INC. (CONTINUED).....	299

<i>TABLE 126 AGILENT ACQUISITIONS, 2007–2009</i> .....	300
AGNITIO SCIENCE AND TECHNOLOGY .....	301
ALLEGRO DIAGNOSTICS, INC. ....	302
ALMAC GROUP, LTD. ....	302
APPLIED MICROARRAYS, INC. ....	303
APPLIED MICROARRAYS, INC. (CONTINUED).....	304
ARRAYIT CORP. ....	305
ARRAYJET, LTD. ....	305
ARRAYON BIOTECHNOLOGY .....	306
ASPER BIOTECH.....	306
ASTERAND.....	306
AUSHON BIOSYSTEMS, INC.....	307
AUTOGENOMICS, INC. ....	307
<i>TABLE 127 AUTOGENOMICS MICROARRAY-BASED DIAGNOSTICS</i>	
<i>PIPELINE</i> .....	308
AYANDA BIOSYSTEMS S.A. ....	308
BAYER AG .....	309
<i>TABLE 128 CELL LYSATE MICROARRAYS VERSUS WESTERN BLOT</i> ...	310
BECTON DICKINSON.....	311
BIACORE AB .....	311
BIOCARTIS S.A. ....	312
BIODOT, INC.....	312
BIOLOC, LLC .....	312
BIOMICRO SYSTEMS, INC. ....	313
BIO-RAD LABORATORIES, INC. ....	313
BIOSITE, INC. ....	314
BIOTHERANOSTICS.....	315
BIOTRAY.....	315
BIOTROVE, INC.....	316
BLUEGNOME, LTD. ....	316
BODITECH MED, INC.....	317
CALIPER LIFE SCIENCES.....	317
CALIPER LIFE SCIENCES (CONTINUED) .....	318
CALIPER LIFE SCIENCES (CONTINUED) .....	319
CAPITALBIO CORP. ....	320
CAPITALBIO CORP. (CONTINUED).....	321
CELLECTRICON AB .....	322
CELLIX, LTD. ....	322
CELL-KINETICS, LTD. ....	323
CEPHEID .....	324
<i>TABLE 129 COMMERCIAL STATUS OF CEPHEID CLINICAL</i>	
<i>DIAGNOSTIC TESTS BASED ON XPERT AND SMARTCYCLER</i>	
<i>PLATFORMS</i> .....	325
CEPHEID (CONTINUED).....	326

CLAROS DIAGNOSTICS.....	327
CLONTECH LABORATORIES.....	328
COMBIMATRIX CORP. ....	329
<i>TABLE 130 COMBIMATRIX DNA MICROARRAY PLATFORMS.....</i>	<i>329</i>
<i>TABLE 131 COMBIMATRIX DNA MICROARRAY-BASED LAUNCHED</i>	
<i>DIAGNOSTICS.....</i>	<i>330</i>
COVENTOR, INC. ....	331
CRYSTAL VISION MICROSYSTEMS S.A.....	331
CYCLOFLUIDIC.....	332
DEBIOTECH S.A.....	332
DIAGENIC ASA.....	332
DIAGENIC ASA (CONTINUED) .....	333
<i>TABLE 132 DIAGENIC PATENT PORTFOLIO .....</i>	<i>334</i>
DIAGNOSWISS S.A.....	334
DNAVISION S.A.....	335
DYCONEX AG .....	336
ECOARRAY, INC.....	337
EDEL THERAPEUTICS S.A.....	337
EKSIGENT TECHNOLOGIES .....	338
EPIGEM, LTD.....	338
EXIQON A/S.....	339
EXONHIT THERAPEUTICS S.A. ....	340
<i>TABLE 133 EXONHIT'S SPLICE-ARRAY DIAGNOSTICS PIPELINE .....</i>	<i>340</i>
EXONHIT THERAPEUTICS S.A. (CONTINUED) .....	341
FEBIT BIOTECH GMBH.....	342
FLUIDIGM CORP.....	342
FLUIDIGM CORP. (CONTINUED) .....	343
FLUIGENT.....	344
FLUXION BIOSCIENCES INC. ....	344
GE HEALTHCARE LIFE SCIENCES, LTD. ....	344
GENETIX, LTD.....	345
GENEWAVE S.A.S. ....	346
GENOMICS USA, INC.....	347
GENPROBE, INC. ....	347
GENTEL BIOSCIENCES, INC.....	348
GLYCOMINDS, LTD.....	349
GRACE BIO-LABS, INC.....	349
GREINER BIO-ONE GMBH .....	350
<i>TABLE 134 GREINER BIO-ONE BIOCHIP-BASED DIAGNOSTICS</i>	
<i>PIPELINE .....</i>	<i>350</i>
GYROS AB .....	351
HANDYLAB, INC. ....	352
HIGH THROUGHPUT GENOMICS, INC.....	353
HOLOGIC, INC.....	353

IBIDI GMBH .....	354
ICX TECHNOLOGIES .....	354
ILLUMINA, INC. ....	355
<i>TABLE 135 ILLUMINA SEQUENCING TECHNOLOGY SPACE</i> .....	<i>356</i>
IMMUCOR, INC. ....	357
INDEVR, INC.....	358
INVERNESS MEDICAL INNOVATIONS, INC.....	358
IRIS BIOTECHNOLOGIES .....	359
JOHNSON & JOHNSON AMIC AB .....	360
KINEXUS BIOINFORMATICS CORP. ....	361
LC SCIENCES .....	361
LIFE BIOSCIENCE, INC.....	362
LIFE TECHNOLOGIES, INC. ....	363
LIFE TECHNOLOGIES, INC. (CONTINUED) .....	364
LUMINEX .....	365
<i>TABLE 136 LUMINEX MDX PIPELINE</i> .....	<i>366</i>
<i>TABLE 137 LUMINEX PARTNER SUMMARY</i> .....	<i>367</i>
MICRALYNE, INC. ....	368
MICROCHIPS, INC. ....	368
MICROFLUIDIC SYSTEMS, INC. ....	369
MICROLIQUID.....	370
MICRONICS, INC. ....	370
MICRONIT MICROFLUIDICS.....	371
MICROPLUMBERS MICROSCIENCES, LLC .....	371
MILLIPORE .....	372
MOBIDIAG, LTD. ....	372
MOLECULAR PROFILING INSTITUTE .....	373
NANOSPHERE.....	374
NANOSURFACE BIOSCIENCES .....	374
NUVERA BIOSCIENCES .....	375
OCIMUM BIOSOLUTIONS, LTD. ....	376
ORIGENE TECHNOLOGIES, INC. ....	376
OSMETECH MOLECULAR DIAGNOSTICS.....	377
OSMETECH MOLECULAR DIAGNOSTICS (CONTINUED) .....	378
OY JURILAB, LTD. ....	379
PAMGENE INTERNATIONAL B.V. ....	380
PANAGENE, INC. ....	380
PATHWORK DIAGNOSTICS .....	381
PEPSCAN PRESTO B.V.....	382
PERKINELMER .....	382
PERKINELMER (CONTINUED).....	383
PERLEGEN SCIENCES, INC.....	384
PROMEGA CORP. ....	384
PROTAGEN AG .....	385



QUANTRX BIOMEDICAL CORP.....	386
QUEST DIAGNOSTICS .....	387
RANDOX LABORATORIES, LTD. ....	388
<i>TABLE 138 RANDOX BIOCHIPS ASSAYS PORTFOLIO</i> .....	<i>389</i>
ROCHE LIFE SCIENCES.....	390
ROCHE LIFE SCIENCES (CONTINUED).....	391
SEQUENOM, INC. ....	392
SEQUENOM, INC. (CONTINUED).....	393
SCHOTT JENA GLASS GMBH .....	394
SIEMENS AG.....	395
SIGMA ALDRICH CORP. ....	395
<i>TABLE 139 SIGMA ALDRICH ACQUISITIONS, 2006–2009</i> .....	<i>396</i>
SIGNATURE GENOMIC LABORATORIES, LLC.....	397
SIRS-LAB GMBH .....	398
SPINX TECHNOLOGIES .....	398
SQI DIAGNOSTIC SYSTEMS .....	399
STMICROELECTRONICS.....	400
SUPERBIOCHIP LABORATORIES.....	401
SURMODICS, INC. ....	401
TESSARAE.....	402
THINXXS MICROTECHNOLOGY AG.....	402
TRANSLUME, INC. ....	403
VEREDUS LABORATORIES PTE, LTD.....	403
VERENIUM CORP. ....	404
WASATCH MICROFLUIDICS.....	405
WEIDMAN PLASTICS TECHNOLOGIES.....	405
WETWARE CONCEPTS S.R.L. ....	406
XCEED MOLECULAR .....	406
XENOPORE .....	407
ZEPTOSENS AG.....	407
ZEPTOSENS AG (CONTINUED) .....	408